Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011

A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann, H. J. Senn

Research output: Contribution to journalArticle

Abstract

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.

Original languageEnglish
Pages (from-to)1736-1747
Number of pages12
JournalAnnals of Oncology
Volume22
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

Breast Neoplasms
Therapeutics
Patient Preference
Dissection
Radiotherapy
Economics
Gene Expression
Drug Therapy
human ERBB2 protein

Keywords

  • Adjuvant therapies
  • Early breast cancer
  • St Gallen consensus
  • Subtypes

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Strategies for subtypes-dealing with the diversity of breast cancer : Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. / Goldhirsch, A.; Wood, W. C.; Coates, A. S.; Gelber, R. D.; Thürlimann, B.; Senn, H. J.

In: Annals of Oncology, Vol. 22, No. 8, 2011, p. 1736-1747.

Research output: Contribution to journalArticle

@article{1227421d667c4467ae678ae3b1dd829b,
title = "Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011",
abstract = "The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.",
keywords = "Adjuvant therapies, Early breast cancer, St Gallen consensus, Subtypes",
author = "A. Goldhirsch and Wood, {W. C.} and Coates, {A. S.} and Gelber, {R. D.} and B. Th{\"u}rlimann and Senn, {H. J.}",
year = "2011",
doi = "10.1093/annonc/mdr304",
language = "English",
volume = "22",
pages = "1736--1747",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Strategies for subtypes-dealing with the diversity of breast cancer

T2 - Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011

AU - Goldhirsch, A.

AU - Wood, W. C.

AU - Coates, A. S.

AU - Gelber, R. D.

AU - Thürlimann, B.

AU - Senn, H. J.

PY - 2011

Y1 - 2011

N2 - The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.

AB - The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classification. Thus, 'Luminal A' disease generally requires only endocrine therapy, which also forms part of the treatment of the 'Luminal B' subtype. Chemotherapy is considered indicated for most patients with 'Luminal B', 'Human Epidermal growth factor Receptor 2 (HER2) positive', and 'Triple negative (ductal)' disease, with the addition of trastuzumab in 'HER2 positive' disease. Progress was also noted in defining better tolerated local therapies in selected cases without loss of efficacy, such as accelerated radiation therapy and the omission of axillary dissection under defined circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.

KW - Adjuvant therapies

KW - Early breast cancer

KW - St Gallen consensus

KW - Subtypes

UR - http://www.scopus.com/inward/record.url?scp=79960980007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960980007&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr304

DO - 10.1093/annonc/mdr304

M3 - Article

C2 - 21709140

AN - SCOPUS:79960980007

VL - 22

SP - 1736

EP - 1747

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -